NCT06077500 2026-04-14
DAREONᵀᴹ-8
Boehringer Ingelheim
Phase 1 Active not recruiting
Clinical Trials
44 trialsNCT05595460 2026-04-13
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
RayzeBio, Inc.
Phase 1 Active not recruiting
NCT05815160 2026-03-30
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
Debiopharm International SA
Phase 1 Active not recruiting
NCT03420963 2026-03-20
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05361395 2026-03-03
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Amgen
Phase 1 Active not recruiting
NCT05403723 2026-02-19
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
University of Maryland, Baltimore
Phase 1 Suspended
NCT07009457 2025-07-04
Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT03567642 2025-07-03
A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04870112 2025-04-17
SCope-D1
AstraZeneca
Phase 1 Terminated
NCT03509012 2025-01-14
CLOVER
AstraZeneca
Phase 1 Completed
NCT06732258 2024-12-27
Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
Sichuan University
Phase 1 Not yet recruiting
NCT02815592 2024-09-04
Trial of BMS-986012 in Combination With Platinum and Etoposide
Bristol-Myers Squibb
Phase 1 Completed
NCT03850067 2024-08-26
A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer
Celgene
Phase 1 Completed
NCT05116007 2024-05-31
Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC
Akeso
Phase 1 Completed
NCT03963414 2023-08-28
A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
University of Nebraska
Phase 1 Terminated
NCT05026593 2023-07-19
A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT02987998 2022-12-19
Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT04346914 2022-05-11
Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer
Lee's Pharmaceutical Limited
Phase 1 Unknown
NCT04422210 2021-11-08
A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
Hoffmann-La Roche
Phase 1 Terminated
NCT05001412 2021-08-12
Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC
Guangzhou Institute of Respiratory Disease
Phase 1 Unknown
NCT01840579 2021-06-22
MK-3475-011
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01958372 2020-11-23
Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT03116971 2020-09-16
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
EMD Serono
Phase 1 Terminated
NCT02819999 2020-03-12
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
AbbVie
Phase 1 Terminated
NCT02949895 2019-08-12
Study of BMS-986012 in Subjects With Small Cell Lung Caner
Bristol-Myers Squibb
Phase 1 Completed
NCT00926640 2018-10-19
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00807755 2018-01-09
Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors
University of California, Davis
Phase 1 Terminated
NCT02194049 2018-01-09
Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer
University of California, Davis
Phase 1 Completed
NCT01579929 2017-08-17
Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00958022 2017-06-22
Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer
University of Pittsburgh
Phase 1 Terminated
NCT00776698 2016-11-02
A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
Hoffmann-La Roche
Phase 1 Completed
NCT01565772 2016-02-17
Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer
Massachusetts General Hospital
Phase 1 Terminated
NCT00006126 2015-11-13
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
Northwestern University
Phase 1 Withdrawn
NCT01411098 2015-11-04
Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
University of Washington
Phase 1 Terminated
NCT00544596 2014-04-02
R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005022 2013-11-04
Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer
Radiation Therapy Oncology Group
Phase 1 Completed
NCT00002887 2013-09-17
Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00927875 2013-06-03
A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 1 Completed
NCT00042835 2013-02-01
Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00017251 2013-01-24
Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00621361 2012-12-17
Phase I Safety and Tolerability Study of Cediranib (RECENTINâ„¢, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
AstraZeneca
Phase 1 Completed
NCT01604863 2012-11-01
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
GlaxoSmithKline
Phase 1 Suspended
NCT00006487 2012-10-04
S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer
SWOG Cancer Research Network
Phase 1 Completed
NCT01416961 2012-08-22
Integration of Neutron Therapy in the Treatment Plan for Stage III Non-Small Cell Lung Cancer (NSCLC)
Barbara Ann Karmanos Cancer Institute
Phase 1 Withdrawn